表观遗传修饰在癌症发展中起着至关重要的作用，我们的研究利用公共数据进行分析，发现lncRNA中显着的表观遗传异常，为肾癌的预后和治疗策略提供有价值的见解。公共数据来自癌症基因组Atlas (TCGA)、国际癌症基因组联盟 (ICGC) 和基因表达综合 (GEO) 数据库。对网上公开数据的分析全部在R软件中完成。我们发现了肾癌中lncRNA的大量表观遗传异常，这是通过比较lncRNA启动子和增强子上组蛋白区域的以下修饰和甲基化变化来实现的： H3K27ac、H3K4me1、H3K4me3。结果，鉴定出肾癌中 lncRNA 基因的 12 种特定表观遗传疾病。最后，基于该lncRNA，我们研究了肾癌样本的预后，其中8个lncRNA可以被视为肾癌预后的标志物，对ccRCC预后具有很强的预测能力。同时，高风险评分可能对阿西替尼和尼罗替尼产生更好的反应，但对索拉非尼或舒尼替尼则不然。此外，我们观察到免疫治疗无反应者的风险评分水平升高。此外，还进行了生物富集和免疫浸润分析，以调查高风险或低风险患者之间的根本差异。我们的研究提高了对表观遗传失调的长非编码RNA在肾癌中功能的理解。版权所有©2024 Wang，窦、孙、郑、吴、刘、陶。

Epigenetic modifications play a crucial role in cancer development, and our study utilized public data to analyze which leads to the discovery of significant epigenetic abnormalities in lncRNAs, offering valuable insights into prognosis and treatment strategies for renal carcinoma.Public data were obtained from the Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC) and Gene Expression Omnibus (GEO) database. The analysis of the online public data was all completed in R software.We discovered a great number of epigenetic abnormalities of lncRNA in renal cancer, which is achieved by comparing the following modification and methylation of histone region changes on the promoter and enhancer of lncRNA: H3K27ac, H3K4me1, H3K4me3. As a result, 12 specific epigenetic disorders of lncRNA genes in renal cancer were identified. Finally, based on this lncRNA, we investigated the prognosis of renal cancer samples, among which 8 lncRNA can be seen as markers of prognosis in renal cancer, which had great prediction ability for ccRCC prognosis. Meanwhile, high risk score may pose response better to axitinib and nilotinib, but not sorafenib or sunitinib. Beyond, we observed an elevated level of risk score in immunotherapy non-responders. Further, biological enrichment and immuno-infiltration analysis was conducted to investigate the fundamental differences between patients categorized as high or low risk.Our research improves the understanding in the function of epigenetic dysregulated long non-coding RNAs in renal carcinoma.Copyright © 2024 Wang, Dou, Sun, Zheng, Wu, Liu and Tao.